Imposing Proposition 65 state-level requirements on chemicals actively regulated under federal purview risks duplicative warnings that undermine public trust in national safety determinations. Since the FDA derives allowable limits from the best available science, overriding federal risk-benefit guidelines with California-specific thresholds triggers unnecessary labeling not reflecting real-world exposures from routine product usage shown to be safe.
CHPA is committed to advancing solutions to illegal sales that penalize criminals and ensure law-abiding consumers continue to have access to a wide range of treatment options, including nonprescription medicines containing PSE.
Find frequently asked questions about OTC oral pain relievers and fever reducers including acetaminophen, aspirin, ibuprofen, ketoprofen, and naproxen sodium.
This proposed safety administrative order addresses the GRASE status of OTC oral health care drug products containing benzocaine alone or with phenol preparations labeled for anesthetic/analgesic indications (21 CFR 356).
CHPA opposes state and local government attempts to restrict the use of FDA-approved color additives as doing so is vital for maintaining a cohesive regulatory framework.
